Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Original Article ㅣ 2013-01-31
23
619
793
Sun Min Lim, Chung Mo Nam, Youn Nam Kim, Sin Ae Lee, Eun Hye Kim, Sung Pil Hong, Tae Il Kim, Won Ho Kim, and Jae Hee Cheon
Abstract : Background/AimsThe symptoms of inflammatory bowel disease (IBD) fluctuate considerably over time. However, it has not been determined whether these symptoms are affected by the menstrual cycle in female IBD patients. This study analyzed the effects of the menstrual cycle on IBD symptom variation.MethodsThis was a prospective study of 91 study subjects (47 IBD patients and 44 healthy controls) who reported daily symptoms and signs throughout their menstrual cycles.ResultsIBD patients had significantly more frequent gastrointestinal symptoms, such as nausea (30% vs 7%, p=0.006), flatulence (53% vs 22%, p=0.003), and abdominal pain as compared to controls (68% vs 38%, p=0.006). The IBD patients also experienced more frequent systemic premenstrual symptoms than the controls (79% vs 50%, p=0.003). More severe abdominal pain (p=0.002) and lower mean general condition scores (p=0.001) were noted during the menstrual phase as compared to the pre- or post-menstrual phase in both groups. IBD patients experienced more frequent premenstrual gastrointestinal symptoms than controls, but their IBD symptoms did not change significantly during the menstrual cycle.ConclusionsKnowledge of the cyclic alterations in gastrointestinal and systemic symptoms may be helpful in determining the true exacerbation of disease in female IBD patients.
Original Article ㅣ 2022-03-15
10
2089
1699
Yuna Kim1,2 , Eugene Han3
, Jae Seung Lee1,2,4
, Hye Won Lee1,2,4
, Beom Kyung Kim1,2,4
, Mi Kyung Kim3
, Hye Soon Kim3
, Jun Yong Park1,2,4
, Do Young Kim1,2,4
, Sang Hoon Ahn1,2,4
, Byung-Wan Lee1,5
, Eun Seok Kang1,5
, Bong-Soo Cha1,5
, Yong-ho Lee1,5
, Seung Up Kim1,2,4
Abstract : Background/Aims: Nonalcoholic fatty liver disease (NAFLD) and obesity are independently associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality in patients with NAFLD. Many NAFLD patients are lean, but their ASCVD risk compared to obese subjects with NAFLD is unclear. Methods: Data from the 2008 to 2011 Korea National Health and Nutrition Examination Surveys database were analyzed (n=4,786). NAFLD was defined as a comprehensive NAFLD score ≥40 or a liver fat score ≥–0.640. ASCVD risk was evaluated using the American College of Cardiology/ American Heart Association guidelines. Results: The frequency of subjects without NAFLD, with obese NAFLD, and with lean NAFLD was 62.4% (n=2,987), 26.6% (n=1,274), and 11.0% (n=525), respectively. Subjects with lean NAFLD had a significantly higher ASCVD score and prevalence of a high ASCVD risk (mean 15.6±14.0, 51.6%) than those with obese NAFLD and without NAFLD (mean 11.2±11.4, 39.8%; mean 7.9±10.9, 25.5%; all p
Original Article ㅣ 2022-05-15
0
693
675
Salih Tokmak1 , Baris Boral2
, Yuksel Gumurdulu1
Abstract : Background/Aims: To investigate the presence of seronegative celiac disease in patients with isolated refractory dyspepsia and gastroesophageal reflux disease (GERD)-related complaints. Methods: This was a single-center, prospective study performed at a tertiary care referral hospital. Among 968 consecutive patients, 129 seronegative patients with tissue damage consistent with Marsh IIIa classification or above were included. The patients were divided into two groups: dyspepsia (n=78) and GERD (n=51). Biopsies were taken from the duodenum regardless of endoscopic appearance, and patients with Marsh IIIa or above damage were advised to consume a gluten-free diet. The Glasgow Dyspepsia Severity (GDS) score, Reflux Symptom Index (RSI), and Biagi score were calculated at baseline and every 3 months. Control endoscopy was performed every 6 months during follow-up. Results: The median follow-up time was 19.9 months (range, 6 to 24 months) in the dyspepsia group and 19.2 months (range, 6 to 24 months) in the GERD group. All the patients were positive for the HLA-DQ2 and DQ8 haplotypes. The differences between the mean GDS scores (14.3±2.1 vs 1.1±0.2, respectively, p
Hye-Kyung Jung1 , Seung Joo Kang2
, Yong Chan Lee3
, Hyo-Joon Yang4
, Seon-Young Park5
, Cheol Min Shin6
, Sung Eun Kim7
, Hyun Chul Lim8
, Jie-Hyun Kim9
, Su Youn Nam10
, Woon Geon Shin11
, Jae Myung Park12
, Il Ju Choi13
, Jae Gyu Kim14
, Miyoung Choi15
, Korean College of Helicobacter and Upper Gastrointestinal Research
Gut Liver 2021;15(2):168-195
Gut Liver 2021;15(5):666-676
Hye-Kyung Jung1 , Seung Joo Kang2
, Yong Chan Lee3
, Hyo-Joon Yang4
, Seon-Young Park5
, Cheol Min Shin6
, Sung Eun Kim7
, Hyun Chul Lim8
, Jie-Hyun Kim9
, Su Youn Nam10
, Woon Geon Shin11
, Jae Myung Park12
, Il Ju Choi13
, Jae Gyu Kim14
, Miyoung Choi15
, Korean College of Helicobacter and Upper Gastrointestinal Research
Gut Liver 2021;15(2):168-195
Takeshi Ogura , Kazuhide Higuchi
Gut Liver 2021;15(2):196-205
Shang-Chin Huang1 , Hau-Jyun Su1
, Jia-Horng Kao1,2,3
, Tai-Chung Tseng1,3
, Hung-Chih Yang1,3
, Tung-Hung Su1,3
, Pei-Jer Chen1,2,3
, Chun-Jen Liu1,2,3
Gut Liver 2021;15(3):451-458